ClinicalTrials.gg
RecruitingNCT07473700Updated Oct 27, 2026

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

A Phase 2 interventional study of TX000045 in Hypertension, Pulmonary and Lung Diseases, Interstitial, sponsored by Tectonic Operating Company, Inc.. Recruiting at 16 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Tectonic Operating Company, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Site recruiting status changed1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Planned enrollment
156th of 286
25 · median 30
Started
2026
with 23 others
Phase 2
93 of 397
13 open now
Primary completion
2027-11
later than 39 of 84 live
Registered
384th of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 156th largest by planned enrollment of the 286 interventional ones that give a count, is one of 24 that started in 2026, is one of 93 in phase 2, reaches primary completion later than 39 of the 84 other live ones, and was the 384th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.

03

Conditions studied

  • Hypertension, Pulmonary
  • Lung Diseases, Interstitial

Keywords

  • Interstitial lung disease
  • pulmonary vascular resistance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater than or equal to (>=) 10 percent (%) lung parenchyma with fibrosis) consistent with idiopathic interstitial pneumonia, ILD in association with connective tissue disease, occupational ILD, or chronic pneumonitis. Chest CTs will be centrally read for eligibility
  • 40% predicted less than or equal to (\<=) forced vital capacity (FVC) \<= 80% predicted at screening
  • At least ONE of the following is required to undergo the first screening visit: Documented diagnostic right heart catheterization (RHC) within 18 months of screening with mean pulmonary arterial pressure (mPAP) >= 25 millimeters of mercury (mm Hg), pulmonary capillary wedge pressure (PCWP) \<=15 mm Hg, and pulmonary vascular resistance (PVR) >=4 Wood units; Documented echocardiogram (ECHO) within 18 months of screening with right ventricular (RV) (or pulmonary artery) systolic pressure >46 mm Hg or tricuspid annular plane systolic excursion (TAPSE)/ systolic pulmonary artery pressure (SPAP) \<=0.38 and absence of left ventricular dysfunction as assessed by the investigator

Exclusion criteria

Exclusion Criteria:

  • Participants have a confirmed or suspected diagnosis of pulmonary hypertension in World Health Organization (WHO) Group 1, WHO Group 2, WHO Group 4, or WHO Group 5
  • Participants have received phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators, intravenous (IV) or subcutaneous (SC) prostacyclin analogues within 30 days before the first screening visit, or sotatercept within 180 days before the first screening visit
  • Participants have any type of pulmonary and cardiovascular comorbidities as defined n protocol
  • Participants who are taking disease-modifying therapy for the underlying interstitial lung disease (ILD) (anti-fibrotics, immunosuppressives, and anti-inflammatory medications) who are not on stable doses for >30 days before the first screening visit or have initiated new ILD-directed therapies within 90 days before the first screening visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    TX000045 300 mg

    Participants will receive subcutaneous (SC) injection of TX000045 at a dose of 300 milligrams (mg) every 4 weeks (Q4W) from Week 1 up to Week 13.

    Drug: TX000045

Interventions

  • DrugTX000045

    Subcutaneous Injection.

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in PVR up to 16 Weeks

    Time frame: Baseline up to 16 weeks

  2. Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to 21 weeks

  3. Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory Assessments, 12-Lead Electrocardiogram (ECG) Assessments and Vital Sign Assessments

    Time frame: Baseline up to 21 weeks

Secondary outcomes

  1. Mean Change from Baseline in Mean Pulmonary Arterial Pressure (mPAP) up to 21 Weeks

    Time frame: Baseline up to 21 weeks

  2. Mean Change from Baseline in Hemodynamic Parameter: Pulmonary Capillary Wedge Pressure (PCWP)

    Time frame: Baseline up to 21 weeks

  3. Mean Change from Baseline in Hemodynamic Parameter: Cardiac Output (CO)

    Time frame: Baseline up to 21 weeks

  4. Mean Change from Baseline in Hemodynamic Parameter: Stroke Volume (SV)

    Time frame: Baseline up to 21 weeks

  5. Mean Change from Baseline in Resting Arterial Oxygen Saturation (SpO2) up to 21 Weeks

    Time frame: Baseline up to 21 weeks

  6. Mean Change from Baseline in Supplemental Oxygen Requirement (L/min) up to 21 Weeks

    Time frame: Baseline up to 21 weeks

  7. Mean Change from Baseline in the Nadir of the SpO2 During the 6-minute walk test (6MWT) up to 21 Weeks

    Time frame: Baseline up to 21 weeks

  8. Mean Change from Baseline in Oxygen Saturation (SpO2)at 1, 2, and 3 Minutes after Completion of the 6-MWT up to 21 Weeks

    Time frame: Baseline up to 21 weeks

  9. Mean Change from Baseline in Distance Walked During the 6MWT at Which an Absolute Decrease of SpO2>4% for At least 15 Second

    Time frame: Baseline up to 21 weeks

07

Study locations

12 of 16 sites recruiting
  • Phoenix
    Phoenix, Arizona 85020, United States
    Recruiting
  • San Francisco
    San Francisco, California 94143, United States
    Recruiting
  • Idaho
    Boise, Idaho 83706, United States
    Not yet recruiting
  • Allen Park
    Allen Park, Michigan 48101, United States
    Recruiting
  • Krakow
    Krakow, 31-202, Poland
    Not yet recruiting
  • Lublin
    Lublin, 20-950, Poland
    Not yet recruiting
  • Wroclaw
    Wroclaw, 50-556, Poland
    Recruiting
  • Bucharest
    Bucharest, 11658, Romania
    Recruiting
  • Belgrade
    Belgrade, 11000, Serbia
    Recruiting
  • Sremska Kamenica
    Kamenitz, 21204, Serbia
    Recruiting
  • Niš
    Niš, 18000, Serbia
    Recruiting
  • Gyeonggi-Do
    Gyeonggi-do, 14353, South Korea
    Recruiting
  • Seoul
    Seoul, 05505, South Korea
    Recruiting
  • Barcelona
    Barcelona, 08002, Spain
    Not yet recruiting
  • Madrid
    Madrid, 28046, Spain
    Recruiting
  • Santander
    Santander, 39011, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2027, 12 months later.

Of 50 phase 2 interventional studies under Hypertension, Pulmonary, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 71. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 16, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Nov 21, 2027
CompletionEst.
Dec 11, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed. 10 sites changed recruiting status (10 now recruiting)
Show 10 sites
  • Allen Park · Allen Park, United StatesNot yet recruiting→Recruiting
  • Wroclaw · Wroclaw, PolandNot yet recruiting→Recruiting
  • Bucharest · Bucharest, RomaniaNot yet recruiting→Recruiting
  • Belgrade · Belgrade, SerbiaNot yet recruiting→Recruiting
  • Sremska Kamenica · Kamenitz, SerbiaNot yet recruiting→Recruiting
  • Niš · Niš, SerbiaNot yet recruiting→Recruiting
  • Gyeonggi-Do · Gyeonggi-do, South KoreaNot yet recruiting→Recruiting
  • Seoul · Seoul, South KoreaNot yet recruiting→Recruiting
  • Madrid · Madrid, SpainNot yet recruiting→Recruiting
  • Santander · Santander, SpainNot yet recruiting→Recruiting
Show site
  • Idaho · Boise, United States
Show 1 removed
  • Idaho · Idaho Falls, United States
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    1 site added, 1 site removed. 10 sites changed recruiting status (10 now recruiting)
    Show 10 sites
    • Allen Park · Allen Park, United StatesNot yet recruiting→Recruiting
    • Wroclaw · Wroclaw, PolandNot yet recruiting→Recruiting
    • Bucharest · Bucharest, RomaniaNot yet recruiting→Recruiting
    • Belgrade · Belgrade, SerbiaNot yet recruiting→Recruiting
    • Sremska Kamenica · Kamenitz, SerbiaNot yet recruiting→Recruiting
    • Niš · Niš, SerbiaNot yet recruiting→Recruiting
    • Gyeonggi-Do · Gyeonggi-do, South KoreaNot yet recruiting→Recruiting
    • Seoul · Seoul, South KoreaNot yet recruiting→Recruiting
    • Madrid · Madrid, SpainNot yet recruiting→Recruiting
    • Santander · Santander, SpainNot yet recruiting→Recruiting
    Show site
    • Idaho · Boise, United States
    Show 1 removed
    • Idaho · Idaho Falls, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07473700
Lead sponsor
Tectonic Operating Company, Inc.
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Nov 21, 2027 (estimated)
Completion
Dec 11, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Clinical Trials
Contact
ClinicalTrials@tectonictx.com
+1 339 337 4053

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion